NovaBay Pharmaceuticals Inc.

NovaBay Pharmaceuticals Inc. is a biopharmaceutical company focused on commercializing and developing its nonantibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market. The company's Neutrox family of products includes Avenova for the eye care market, Neutrophase for wound care market and CelleRx for the cosmetic surgery and aesthetic dermatology market; they have been cleared by the U.S. FDA as 510(k) medical devices. NovaBay's other focuses are its Aganocide compounds, led by Auriclosene, which is in development as a new drug in urology and dermatology. NovaBay is partnered in the U.S. and around the globe.